10-QPeriod: Q1 FY2023

BeOne Medicines Ltd. Quarterly Report for Q1 Ended Mar 31, 2023

Filed May 4, 2023For Securities:ONCBEIGF

Summary

BeiGene, Ltd. (ONC) reported a solid increase in total revenues for the first quarter of 2023, driven primarily by a substantial 56.9% year-over-year growth in net product revenue. This growth was largely fueled by strong performance in BRUKINSA sales, which more than doubled, and a notable 31.0% increase in tislelizumab sales, both benefiting from expanded market access and reimbursement in key markets like China and the U.S. While revenues are increasing, the company continues to invest heavily in research and development, leading to a net loss of $348.4 million for the quarter. Despite the ongoing net loss, BeiGene ended the quarter with a strong cash position of $3.54 billion, providing a significant runway for its extensive clinical development programs and global expansion efforts. The company's liquidity appears sufficient for the next twelve months, but future funding needs for its ambitious pipeline remain a consideration.

Financial Highlights

53 data points
Beta

Revenue

$447.80M

81.7% Gross Margin

Net Income

-$348.43M

-77.8% Net Margin

EPS (Diluted)

$-0.26

Total Assets

$5.96B

Cash & Equivalents

$3.54B

Free Cash Flow

-$689.36M

Financial Statements
Beta
Revenue$447.80M
Cost of Revenue$81.79M
Gross Profit$366.01M
R&D Expenses$408.58M
SG&A Expenses$328.50M
Operating Expenses$737.27M
Operating Income-$371.26M
Interest Expense$4.57M
Net Income-$348.43M
EPS (Basic)$-0.26
EPS (Diluted)$-0.26
Shares Outstanding (Basic)1.35B
Shares Outstanding (Diluted)1.35B

Key Highlights

  • 1Total revenues increased by 46.0% to $447.8 million in Q1 2023 compared to Q1 2022.
  • 2Net product revenue grew significantly by 56.9% to $410.3 million, driven by strong sales of BRUKINSA and tislelizumab.
  • 3BRUKINSA sales increased by 102.6% to $211.4 million, with U.S. sales showing robust growth.
  • 4Tislelizumab sales in China increased by 31.0% to $114.9 million.
  • 5Research and development expenses increased by 4.8% to $408.6 million, reflecting continued investment in the pipeline.
  • 6The company reported a net loss of $348.4 million for the quarter.
  • 7Cash, cash equivalents, and restricted cash stood at $3.54 billion as of March 31, 2023, indicating a healthy liquidity position.

Frequently Asked Questions

Revenue growth was primarily driven by a 56.9% increase in net product revenue, totaling $410.3 million. This was largely due to strong sales performance of BRUKINSA, which saw a 102.6% increase to $211.4 million, and tislelizumab sales in China, which grew 31.0% to $114.9 million. Expanded market access, reimbursement in key regions, and increased patient demand for these core products were key factors.

BeiGene continues to invest heavily in research and development, with R&D expenses increasing by 4.8% to $408.6 million in Q1 2023. This reflects ongoing clinical trials and development programs. While this investment contributes to the net loss of $348.4 million for the quarter, the company is strategically expanding its commercial capabilities and R&D organization to support its growing pipeline.

BeiGene maintains a strong liquidity position, ending the first quarter of 2023 with $3.54 billion in cash, cash equivalents, and restricted cash. The company reported that its existing cash resources are expected to fund its operating expenses and capital expenditure requirements for at least the next twelve months. This robust cash balance provides significant financial flexibility for its ongoing clinical development and global commercialization efforts.

Collaboration revenue decreased by 16.7% to $37.5 million in Q1 2023 compared to $45.1 million in Q1 2022. This decrease was primarily due to a reduction in research and development service revenue recognized from the Novartis collaborations, although the right to access intellectual property revenue remained consistent.